Please assess the completion status of the following clinical trial:

Trial Title: Ketorolac Versus Ibuprofen to Treat Painful Episodes of Sickle Cell Disease

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of any form of SCD, including sickle cell anemia, sickle-hemoglobin C disease, and sickle-ß˖ or ß°-thalassemia~* Currently experiencing an acute painful episode (vaso-occlusive crisis), defined as acute pain in the extremities, back, abdomen, or chest that has lasted at least 4 hours and is presumed to be due to SCD, with no other identified cause~* Onset of severe pain in its current location(s) must have occurred within 72 hours of study entry~* Intensity of pain must be great enough to necessitate hospitalization for opioid analgesia (e.g., failure of home and outpatient therapy)~* Ability to comprehend and use patient-controlled analgesia (PCA)~* Score of 6 or greater on the baseline pain scale~Exclusion Criteria:~* Temperature greater than or equal to 38.5ºC at the time of study entry or in the preceding 12 hours~* Has a new lobar pulmonary infiltrate or a diagnosis of acute chest syndrome (i.e., a new lobar pulmonary infiltrate and two or more of the following: temperature greater than 38ºC, tachypnea, dyspnea, intercostal or supraclavicular retractions, nasal flaring, chest wall pain, and an oxygen saturation of less than 90% in room air by pulse oximetry)~* Diagnosis of acute splenic or hepatic sequestration crisis (i.e., liver or spleen enlarged from steady-state size and Hgb level decreased 2 g/dL or more from steady-state value)~* Currently experiencing priapism~* Pain caused by suspected or confirmed hepatobiliary disease (e.g., cholecystitis or cholelithiasis)~* Chronic pain caused by suspected or confirmed aseptic or avascular necrosis of the femoral or humeral heads~* Chronic pain syndrome characterized by opioid tolerance and defined by hospitalization for at least 30 days for the management of pain in a 1 year period prior to study entry~* Current participation (last transfusion given within the 2 months prior to study entry) in a program of chronic transfusions for the management of SCD; the use of hydroxyurea alone is permitted~* Allergy or history of anaphylactoid reactions to aspirin or other NSAIDs~* Kidney dysfunction (i.e., serum creatinine concentration greater than 1.5 times the upper limit of normal for age)~* History of gastrointestinal bleeding or ulceration requiring medical therapy~* Concomitant bleeding disorder (e.g., von Willebrand disease, hemophilia, or a qualitative platelet defect)~* Any other medical condition that would make it unsafe to receive NSAIDs, as determined by the study physician~* PCA not preferred~* Use of ketorolac in the 30 days prior to study entry~* Use of scheduled (e.g., around the clock) opioid analgesics in the 5 days before the onset of current acute painful crisis~* Pregnant

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 18 Years
- Healthy Volunteers: f

Study Arms:
- 1-Intravenous ketorolac and oral placebo (Type: ACTIVE_COMPARATOR): Intravenous ketorolac and oral placebo
- 2-Intravenous placebo and oral ibuprofen (Type: ACTIVE_COMPARATOR): Intravenous placebo and oral ibuprofen

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: enrollment issues